Key result
Silencing the mineralocorticoid receptor in mesenchymal stem cells improved cell survival, enhanced cardiac function, and reduced infarct size in a rat model of myocardial infarction.
Why the study?
Poor stem cell survival limits therapeutic efficacy for myocardial infarction, and mineralocorticoid receptor activation contributes to cardiovascular disease pathogenesis.
Does mineralocorticoid receptor silencing in mesenchymal stem cells improve their survival and cardioprotective effects in a rat model of myocardial infarction?
Does mineralocorticoid receptor silencing in mesenchymal stem cells improve their survival and cardioprotective effects in a rat model of myocardial infarction?
Silencing the mineralocorticoid receptor in mesenchymal stem cells enhances their survival and therapeutic efficacy in a rat model of myocardial infarction.
The poor survival of stem cells seriously limits their therapeutic efficacy for myocardial infarction (MI). Mineralocorticoid receptor (MR) activation plays an important role in the pathogenesis of multiple cardiovascular diseases. Here, we examined whether MR silencing in bone marrow derived mesenchymal stem cells (MSCs) could improve MSCs’ survival and enhance their cardioprotective effects in MI. MSCs from male Sprague‐Dawley rats were transfected with adenoviral small interfering RNA to silence MR (siRNA‐MR). MR silencing decreased hypoxia‐induced MSCs’ apoptosis, as demonstrated by Annexin V/7‐AAD staining. The mechanisms contributing to the beneficial effects of MR depletion were associated with inhibiting intracellular reactive oxygen species production and increased Bcl‐2/Bax ratio. In vivo study, 1 × 106 of MSCs with or without siRNA‐MR were injected into rat hearts immediately after MI. Depletion of MR could improve the MSCs’ survival significantly in infarcted myocardium, associated with more cardiac function improvement and smaller infarct size. Capillary density were also significantly higher in siRNA group with increased expression of vascular endothelial growth factor. Our study demonstrated that silencing MR promoted MSCs’ survival and repair efficacy in ischaemic hearts. MR might be a potential target for enhancing the efficacy of cell therapy in ischaemic heart disease.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2018) studied Myocardial infarction. Mesenchymal stem cells with mineralocorticoid receptor silenced via siRNA (siRNA-MR) vs. Mesenchymal stem cells without siRNA-MR was evaluated on MSC survival, cardiac function, and infarct size. Silencing the mineralocorticoid receptor in mesenchymal stem cells improved cell survival, enhanced cardiac function, and reduced infarct size in a rat model of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: